Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cartesian Therapeutics (RNAC) Revenue: 2014-2024

Historic Revenue for Cartesian Therapeutics (RNAC) over the last 11 years, with Dec 2024 value amounting to $38.9 million.

  • Cartesian Therapeutics' Revenue rose 16.80% to $452,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 million, marking a year-over-year decrease of 97.72%. This contributed to the annual value of $38.9 million for FY2024, which is 49.64% up from last year.
  • Per Cartesian Therapeutics' latest filing, its Revenue stood at $38.9 million for FY2024, which was up 49.64% from $26.0 million recorded in FY2023.
  • Cartesian Therapeutics' Revenue's 5-year high stood at $110.8 million during FY2022, with a 5-year trough of $16.6 million in FY2020.
  • Its 3-year average for Revenue is $58.6 million, with a median of $38.9 million in 2024.
  • As far as peak fluctuations go, Cartesian Therapeutics' Revenue surged by 412.60% in 2021, and later tumbled by 76.53% in 2023.
  • Yearly analysis of 5 years shows Cartesian Therapeutics' Revenue stood at $16.6 million in 2020, then spiked by 412.60% to $85.1 million in 2021, then skyrocketed by 30.21% to $110.8 million in 2022, then slumped by 76.53% to $26.0 million in 2023, then spiked by 49.64% to $38.9 million in 2024.